Hammer Asset Management LLC Invests $1.44 Million in Eli Lilly And Co (NYSE:LLY)

Hammer Asset Management LLC purchased a new position in shares of Eli Lilly And Co (NYSE:LLY) during the third quarter, Holdings Channel.com reports. The fund purchased 12,900 shares of the company’s stock, valued at approximately $1,443,000.

Several other hedge funds have also modified their holdings of the company. Sterling Investment Management Inc. lifted its holdings in Eli Lilly And Co by 41.3% in the third quarter. Sterling Investment Management Inc. now owns 7,988 shares of the company’s stock valued at $893,000 after acquiring an additional 2,333 shares during the period. Campbell Newman Asset Management Inc. lifted its stake in Eli Lilly And Co by 2.3% during the 3rd quarter. Campbell Newman Asset Management Inc. now owns 95,008 shares of the company’s stock worth $10,625,000 after acquiring an additional 2,125 shares in the last quarter. Fiduciary Financial Services of The Southwest Inc. TX lifted its stake in Eli Lilly And Co by 7.4% during the 3rd quarter. Fiduciary Financial Services of The Southwest Inc. TX now owns 12,218 shares of the company’s stock worth $1,366,000 after acquiring an additional 846 shares in the last quarter. Rhumbline Advisers lifted its stake in Eli Lilly And Co by 2.0% during the 3rd quarter. Rhumbline Advisers now owns 1,484,704 shares of the company’s stock worth $166,034,000 after acquiring an additional 28,867 shares in the last quarter. Finally, AdvisorNet Financial Inc lifted its stake in Eli Lilly And Co by 61.1% during the 3rd quarter. AdvisorNet Financial Inc now owns 4,645 shares of the company’s stock worth $519,000 after acquiring an additional 1,761 shares in the last quarter. Institutional investors and hedge funds own 76.75% of the company’s stock.

In other news, SVP Stephen F. Fry sold 9,452 shares of the stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $115.00, for a total value of $1,086,980.00. Following the transaction, the senior vice president now owns 100,211 shares in the company, valued at approximately $11,524,265. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $116.37, for a total value of $24,437,700.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 243,452 shares of company stock worth $28,252,925. Company insiders own 0.11% of the company’s stock.

Several equities analysts recently issued reports on LLY shares. UBS Group decreased their target price on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating on the stock in a research note on Thursday, October 17th. Bank of America assumed coverage on Eli Lilly And Co in a research note on Wednesday, October 16th. They set a “buy” rating and a $133.00 target price on the stock. Finally, ValuEngine lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Seven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $128.31.

LLY opened at $107.84 on Friday. Eli Lilly And Co has a one year low of $101.36 and a one year high of $132.13. The company has a market cap of $103.69 billion, a P/E ratio of 19.43, a PEG ratio of 1.83 and a beta of 0.16. The company has a debt-to-equity ratio of 4.98, a quick ratio of 0.87 and a current ratio of 1.13. The business’s 50-day simple moving average is $110.62 and its 200-day simple moving average is $113.43.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 23rd. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.43 by $0.05. Eli Lilly And Co had a return on equity of 98.17% and a net margin of 35.10%. The business had revenue of $5.48 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter in the prior year, the business posted $1.39 EPS. The business’s revenue for the quarter was up 3.2% on a year-over-year basis. As a group, analysts predict that Eli Lilly And Co will post 5.75 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a $0.645 dividend. The ex-dividend date is Thursday, November 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.39%. Eli Lilly And Co’s payout ratio is currently 46.49%.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: What is a short straddle?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.